Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IPOPEMA SecuritiesWAR:IPE +5.74%57 3-Year EPS without NRI Growth Rate is 37.20% as of Mar. 2026. GuruFocus rates WAR:IPE with a GF Score™ of 57/100 and a GF Value™ of zł3.64 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 583 Capital Markets companies, IPOPEMA Securities ranks better than 71.7% on this metric.
During the past 12 months, IPOPEMA Securities's average EPS without NRI Growth Rate was 236.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 37.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of IPOPEMA Securities was 102.50% per year. The lowest was -47.30% per year. And the median was -14.20% per year.
IPOPEMA Securities (WAR:IPE) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
IPOPEMA Securities 3-Year EPS without NRI Growth Rate Related Terms
WAR:IPE vs MS, GS, SCHW: 3-Year EPS without NRI Growth Rate Comparison
For the Capital Markets subindustry, IPOPEMA Securities's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IPOPEMA Securities 3-Year EPS without NRI Growth Rate vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, IPOPEMA Securities's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where IPOPEMA Securities's 3-Year EPS without NRI Growth Rate falls into.
IPOPEMA Securities 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 37.20% mean?
IPOPEMA Securities (WAR:IPE) has a 3-Year EPS without NRI Growth Rate of 37.20% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IPOPEMA Securities and its competitors. According to the industry distribution chart, IPOPEMA Securities ranks #165 out of 583 companies in the Capital Markets industry, placing it in the top 28.3%.
Is IPOPEMA Securities' 3-Year EPS without NRI Growth Rate too high?
IPOPEMA Securities' current 3-Year EPS without NRI Growth Rate is 37.20%. The Capital Markets industry median 3-Year EPS without NRI Growth Rate is 15.20. IPOPEMA Securities' value of 37.20% is 144.7% above this industry median. Based on the distribution chart, IPOPEMA Securities ranks #165 out of 583 companies in the Capital Markets industry, which is above the industry midpoint. Overall, IPOPEMA Securities has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IPOPEMA Securities' 3-Year EPS without NRI Growth Rate compare to MS and GS?
According to the Capital Markets industry distribution chart, IPOPEMA Securities ranks #165 out of 583 companies for 3-Year EPS without NRI Growth Rate. This puts IPOPEMA Securities in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.20. IPOPEMA Securities' value of 37.20% is 144.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Capital Markets company?
The median 3-Year EPS without NRI Growth Rate among Capital Markets companies is 15.20, based on 583 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IPOPEMA Securities's current 3-Year EPS without NRI Growth Rate of 37.20% is 144.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IPOPEMA Securities and its competitors. For the Capital Markets industry, the median 3-Year EPS without NRI Growth Rate is 15.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IPOPEMA Securities's current 3-Year EPS without NRI Growth Rate is 37.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IPOPEMA Securities stock overvalued right now?
Based on GuruFocus' analysis, IPOPEMA Securities (WAR:IPE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł3.64, compared to a current price of zł9.58 — trading 163.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 37.20% and 144.7% above the Capital Markets industry median of 15.20. IPOPEMA Securities' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For IPOPEMA Securities (WAR:IPE), the current 3-Year EPS without NRI Growth Rate is 37.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IPOPEMA Securities (WAR:IPE) Overvalued in 2026?
Based on GuruFocus' analysis, IPOPEMA Securities stock appears to be overvalued.
The current stock price of zł9.58 is trading 163.2% above its estimated GF Value™ of zł3.64.
GuruFocus considers IPOPEMA Securities to be Significantly Overvalued.
Key valuation signals for WAR:IPE:
3-Year EPS without NRI Growth Rate: 37.20%
GF Value™: zł3.64 vs. price of zł9.58 (163.2% above fair value)
Industry Position: 144.7% above the Capital Markets median (#165 of 583)
No single metric tells the full story. See the WAR:IPE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IPOPEMA Securities SA is focused on brokerage activities, Business and management consulting, running an investment fund company and creating and managing investment funds, Management of portfolios of brokerage financial instruments, IT management activities, and IT consulting activities. It specializes in brokerage and company analysis services, investment banking services, as well as the distribution of investment products and investment advisory services addressed to a wide range of individual investors, the creation and management of closed-end and open-end investment funds and asset management, as well as business and IT consulting services.
57GF Score
Get the complete analysis for WAR:IPE
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:IPE has been successfully added to your 
